8-K: Brainstorm Cell Therapeutics Granted Nasdaq Extension to Regain Compliance, Reverse Stock Split Possible

Brainstorm Cell Therapeutics has received an extension from Nasdaq until October 21, 2024, to regain compliance with the minimum bid price requirement, potentially through a reverse stock split.

Summary

• Brainstorm Cell Therapeutics was previously notified by Nasdaq that it was not in compliance with the $1.00 minimum bid price requirement.
• The company was initially given 180 days to regain compliance, which it failed to meet.
• Nasdaq initially scheduled the company's delisting for May 10, 2024, but Brainstorm requested a hearing to appeal.
• The Nasdaq Hearing Panel has granted Brainstorm a temporary exception until October 21, 2024, to regain compliance.
• This extension is contingent on the company completing a reverse stock split, if necessary, by October 7, 2024.
• Brainstorm aims to regain compliance through other measures before resorting to a reverse stock split.
• If compliance is not achieved by mid-August 2024, a reverse stock split will be required.
• Failure to regain compliance by October 21, 2024, will result in the company's securities being delisted.
• There is no guarantee that a reverse stock split will ensure compliance or positively impact the stock price.

Sentiment

Score: 3

Explanation: The document highlights significant challenges for the company, including the risk of delisting and the potential need for a reverse stock split, which are generally viewed negatively by investors.

Positives

• Brainstorm has been granted an extension to regain compliance with Nasdaq listing rules.
• The company has time to explore options other than a reverse stock split to increase its share price.
• The Nasdaq Hearing Panel has acknowledged the company's plan to regain compliance.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price requirement.
• A reverse stock split may be necessary, which could negatively impact the stock price.
• There is a risk of delisting if compliance is not achieved by October 21, 2024.

Risks

• The company may not be able to regain compliance with the minimum bid price requirement through other measures.
• A reverse stock split could negatively impact the market price of the company's stock.
• Failure to regain compliance by October 21, 2024, will result in delisting from the Nasdaq Capital Market.
• There is no guarantee that a reverse stock split will ensure compliance.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing requirements, potentially through a reverse stock split if other measures are unsuccessful. The company has until October 21, 2024, to achieve this.

Management Comments

• The Company prioritizes regaining compliance with the Minimum Bid Price Requirement through other measures before resorting to a reverse stock split.
• In the event the Company fails to achieve compliance by mid-August 2024, it will be required to undertake a reverse stock split to regain compliance by the October 21, 2024 deadline.

Industry Context

This situation is not uncommon for biotech companies, especially those in the development stage, as they often face challenges in maintaining share prices above minimum thresholds. Delisting from major exchanges can significantly impact investor confidence and access to capital.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum share prices on major exchanges.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced delisting warnings, highlighting the volatility and risk in the biotech sector.
• Reverse stock splits are a common strategy for companies to regain compliance, but they often signal underlying financial or operational issues.
• The success of a reverse stock split in maintaining compliance is not guaranteed, as seen with companies like Agenus (AGEN) which have had to implement multiple reverse splits.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's reputation and ability to attract future investment could be negatively impacted.

Next Steps

• Brainstorm will attempt to regain compliance with the minimum bid price requirement through measures other than a reverse stock split.
• If necessary, Brainstorm will complete a reverse stock split by October 7, 2024.
• Brainstorm must regain compliance by October 21, 2024, to avoid delisting.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, reverse stock split, compliance, BCLI, Brainstorm Cell Therapeutics